From Nasdaq:

The S&P 500’s Q4 profits were up 3%, but the market’s future is uncertain due to inflation and an inverted yield curve. Stocks like Sarepta Therapeutics, Enphase Energy, and Alphabet offer growth potential despite macroeconomic concerns. Sarepta’s gene therapy for muscular dystrophy is gaining traction, with profits expected soon. Enphase’s solar power equipment faces short-term challenges but has long-term growth potential. Alphabet’s advertising revenue is solid, with Google Cloud showing record growth. Analysts expect both revenue and profit growth, leading to a consensus buy rating.



Read more at Nasdaq: Got $1,000? Buy These Hot Growth Stocks Before They Take Off.